Leandro de Sousa Dias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leandro de Sousa Dias has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Allan Kayk Sales Meneses
Postgraduate Program in Chemistry, Organic Geochemistry Laboratory, Department of Chemistry, Federal University of Piauí, Teresina 64049-550, PI, Brazil
1 shared publication - Ana Paula Rodrigues
Federal University of Piaui
1 shared publication - André Luis Menezes Carvalho
Postgraduate Program in Pharmaceutical Sciences, Dermopharmacy Laboratory, Pharmaceutical Technology Center, Federal University of Piauí, Teresina 64049-550, PI, Brazil
1 shared publication - Antonio Do Nascimento Cavalcante
Federal Institute of Maranhão
1 shared publication - Carla Verônica Rodarte de Moura
Postgraduate Program in Chemistry, Biodiesel and Materials Laboratory, Department of Chemistry, Federal University of Piauí, Teresina 64049-550, PI, Brazil
1 shared publication - Chistiane Mendes Feitosa
Federal University of Piaui
1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1229
Co-Delivery of Fluconazole and Riparin B Using Nanostructured Lipid Carriers: A Quality-by-Design Approach for Enhanced Antifungal Activity
Background/Objectives: The increasing incidence of invasive fungal infections and the emergence of antifungal resistance have limited the effectiveness of conventional therapies against Candida spp. This study aimed to develop and optimize nanostructured lipid carriers (NLCs) containing fluconazole (FLC) and Riparin B (RIP) using a systematic Quality-by-Design (QbD) approach. Methods: The optimized NLCs were characterized by particle size, polydispersity index (PDI), zeta potential, DSC, and FTIR analyses. Molecular docking was used as a complementary exploratory approach to investigate possible interactions of RIP with representative components of the lipid matrix and with fungal resistance-associated proteins. Release profiles and antifungal activity against Candida spp. were also evaluated. Results: The optimized NLCs exhibited a mean particle size of 144.9 ± 2.25 nm, PDI of 0.153 ± 0.03, and zeta potential of −27.8 ± 1.81 mV. DSC and FTIR analyses supported the structural organization of the lipid matrix and the formation of an imperfect crystalline network, providing structural defects favorable for the incorporation of the active compounds. RIP exhibited more favorable predicted interactions than FLC within the specific lipid configuration evaluated, although these docking scores should not be interpreted as direct thermodynamic measurements of drug–lipid affinity or as quantitative predictors of encapsulation efficiency. Docking analyses with MdR1, CdR1, and CdR2 identified possible interactions of RIP with these resistance-associated proteins, providing a structural hypothesis that may contribute to understanding the potentiation of FLC activity. However, these computational results do not establish direct efflux-pump inhibition. Release profiles followed distinct kinetic regimes, consistent with matrix relaxation for RIP and Fickian diffusion for FLC. Although RIP alone did not exhibit relevant antifungal activity, its association with FLC potentiated FLC activity against Candida spp., while incorporation of the combination into NLCs produced a further enhancement, significantly reducing the minimum inhibitory concentration. Conclusions: These findings indicate that the optimized NLC platform can enhance the antifungal performance of the FLC–RIP combination and provide a formulation framework for further investigation of this co-delivery strategy.
- 28 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1229
Open AccessCo-Delivery of Fluconazole and Riparin B Using Nanostructured Lipid Carriers: A Quality-by-Design Approach for Enhanced Antifungal Activity
Background/Objectives: The increasing incidence of invasive fungal infections and the emergence of antifungal resistance have limited the effectiveness of conventional therapies against Candida spp. This study aimed to develop and optimize nanostructured lipid carriers (NLCs) containing fluconazole (FLC) and Riparin B (RIP) using a systematic Quality-by-Design (QbD) approach. Methods: The optimized NLCs were characterized by particle size, polydispersity index (PDI), zeta potential, DSC, and FTIR analyses. Molecular docking was used as a complementary exploratory approach to investigate possible interactions of RIP with representative components of the lipid matrix and with fungal resistance-associated proteins. Release profiles and antifungal activity against Candida spp. were also evaluated. Results: The optimized NLCs exhibited a mean particle size of 144.9 ± 2.25 nm, PDI of 0.153 ± 0.03, and zeta potential of −27.8 ± 1.81 mV. DSC and FTIR analyses supported the structural organization of the lipid matrix and the formation of an imperfect crystalline network, providing structural defects favorable for the incorporation of the active compounds. RIP exhibited more favorable predicted interactions than FLC within the specific lipid configuration evaluated, although these docking scores should not be interpreted as direct thermodynamic measurements of drug–lipid affinity or as quantitative predictors of encapsulation efficiency. Docking analyses with MdR1, CdR1, and CdR2 identified possible interactions of RIP with these resistance-associated proteins, providing a structural hypothesis that may contribute to understanding the potentiation of FLC activity. However, these computational results do not establish direct efflux-pump inhibition. Release profiles followed distinct kinetic regimes, consistent with matrix relaxation for RIP and Fickian diffusion for FLC. Although RIP alone did not exhibit relevant antifungal activity, its association with FLC potentiated FLC activity against Candida spp., while incorporation of the combination into NLCs produced a further enhancement, significantly reducing the minimum inhibitory concentration. Conclusions: These findings indicate that the optimized NLC platform can enhance the antifungal performance of the FLC–RIP combination and provide a formulation framework for further investigation of this co-delivery strategy.
- Open Access
- 12 September 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (12)
Piper methysticum G. Forst (Piperaceae) in the central nervous system: phytochemistry, pharmacology and mechanism of action
Due to the continuous increase in incidents of diseases and disorders in the central nervous system as neurodegenerative disease, the growth of studies that seek to use herbal medicines has been observed, since these are more easily produced and more economically viable, in addition to having side effects to a lesser extent when compared to existing synthetic drugs. In this way, a wide variety of plants have been analyzed for their medicinal purposes and this review presents papers published from 1970 to 2021 that describe the chemical composition pharmacological activities and elucidates mechanisms of action in the central nervous system (CNS) of the species Piper methysticum (Kava-kava). The Kava-kava has a class of compounds that include tannins, alkaloids, benzoic acid, cinnamic acid, sugars, bornyl-cinnamate, stigmasterol, flavocavaines, mucilages, pyrones, tetrahydroiangonins, phytochemicals that are responsible for the pharmacological activities of this plant being thus more studied as anxiolytic, sedative and neuroprotection. Some action mechanisms that describe the performance of kava in the CNS were also addressed, Being the main ones related to blocking of sodium and calcium ion channels, modulation of the erythroid 2 pathway, to receptors such as γ-aminobutyric acid, glutamatergics, glycine and cannabinoid, as well as monoamine oxidase and acetylcholinesterase enzymes, in addition to neurotransmitters such as dopamine, serotonin and norepinephrine. Therefore, this study aims to open new paths for more in-depth pharmacological studies on Kava-kava, and its use in the central nervous system.
- 12 September 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (12)
Open AccessPiper methysticum G. Forst (Piperaceae) in the central nervous system: phytochemistry, pharmacology and mechanism of action
Due to the continuous increase in incidents of diseases and disorders in the central nervous system as neurodegenerative disease, the growth of studies that seek to use herbal medicines has been observed, since these are more easily produced and more economically viable, in addition to having side effects to a lesser extent when compared to existing synthetic drugs. In this way, a wide variety of plants have been analyzed for their medicinal purposes and this review presents papers published from 1970 to 2021 that describe the chemical composition pharmacological activities and elucidates mechanisms of action in the central nervous system (CNS) of the species Piper methysticum (Kava-kava). The Kava-kava has a class of compounds that include tannins, alkaloids, benzoic acid, cinnamic acid, sugars, bornyl-cinnamate, stigmasterol, flavocavaines, mucilages, pyrones, tetrahydroiangonins, phytochemicals that are responsible for the pharmacological activities of this plant being thus more studied as anxiolytic, sedative and neuroprotection. Some action mechanisms that describe the performance of kava in the CNS were also addressed, Being the main ones related to blocking of sodium and calcium ion channels, modulation of the erythroid 2 pathway, to receptors such as γ-aminobutyric acid, glutamatergics, glycine and cannabinoid, as well as monoamine oxidase and acetylcholinesterase enzymes, in addition to neurotransmitters such as dopamine, serotonin and norepinephrine. Therefore, this study aims to open new paths for more in-depth pharmacological studies on Kava-kava, and its use in the central nervous system.